The gorgeous live Super Wallpapers found in Xiaomi’s MIUI 12 UI can be used on other devices. Android owners can get them on their phones or tablets without much hassle. And while they are ...

This cutting-edge field represents the convergence of artificial intelligence, sensor technology, and biotechnology. For investors looking beyond the quarterly hype cycle, this emerging sector ...

Shenzhen Genocury Biotech Co., Ltd. is a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress™ platform. This modular delivery system ...

Oversupply and demand dampened by a pullback in venture capital have plagued biotech landlords for more than a year, causing steep increases in vacancy in even the top life sciences markets.

The Lilly-Creyon pact will span “a broad range of diseases," the pair said in a statement, as Lilly buys into the biotech’s so-called “AI-Powered Oligo Engineering Engine.” Creyon debuted ...

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...

What if you just want a few simple pieces of information to show up over your wallpaper? A free application called BeWidgets lets you do just that. This free application lets you set up widgets ...

Biotech firm Jade Biosciences Inc. has completed its merger with Aerovate Therapeutics Inc. (Nasdaq:AVTE), in a move that will put the former on the Nasdaq. Jade’s Vancouver-based CEO, Tom ...

Mer­ck KGaA said Mon­day it has inked a “de­fin­i­tive agree­ment” to ac­quire Pfiz­er spin­out Spring­Works Ther­a­peu­tics for an eq­ui­ty val­ue of around $3.9 bil­lion ...

Investing.com -- HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...